Resultados: 64

    Guidelines on long-acting injectable cabotegravir for HIV prevention

    In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing...

    Consolidated guidelines on person-centred HIV strategic information: strengthening routine data for impact

    As the HIV response moves to focusing on closing the remaining gaps in prevention, testing and treatment services, an evolution in the underlying routine data systems is needed to identify epidemiologic patterns and service gaps, and accelerate focused interventions. These guidelines focus on the collec...

    Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV

    Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa. These guidelines update the recommendations that were first released in 2018 ...

    WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia 

    The leishmaniases are a group of diseases caused by Leishmania spp., which occur in cutaneous, mucocutaneous and visceral forms. They are neglected tropical diseases (NTDs), which disproportionately affect marginalized populations who have limited access to health care. HIV co-infected patients with Leis...

    Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach

    These guidelines provide guidance on the diagnosis of HIV infection, the care of people living with HIV and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection. They are structured along the continuum of HIV testing, prevention, treatment and care. This edition updates the 201...

    Guidelines: updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoringand monitoring: March 2021

    The primary audience for this guideline is national HIV programme managers, people living with HIV, health-care providers and policy-makers in low- and middle-income countries. This guideline update will be a useful resource for clinicians and should help to shape the priorities of policy-makers in devel...

    Updated recommendations on service delivery for the treatment and care of people living with HIV

    WHO promotes a public health approach to programming and delivering antiretroviral therapy (ART), which has enabled access to treatment and care for people living with HIV to be scaled up in resource-limited settings. The 2016 WHO consolidated guidelines on the use of antiretroviral drugs for treating an...

    Preventing HIV through safe voluntary medical male circumcision for adolescent boys and men in generalized HIV epidemics: recommendations and key considerations: guidelines

    Since 2007 the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) have recommended voluntary medical male circumcision (VMMC) as an important strategy for the prevention of heterosexually acquired HIV in men in settings where the prevalence of heterosexually trans...

    Guidelines for Diagnosing and Managing Disseminated Histoplasmosis among People Living with HIV

    Histoplasmosis is a disease caused by the fungus Histoplasma capsulatum. This disease is highly endemic in some regions of North America, Central America, and South America and is also reported in certain countries of Asia and Africa. It often affects people with impaired immunity, including people livin...

    Contraceptive eligibility for women at high risk of HIV: guidance statement: recommendations on contraceptive methods used by women at high risk of HIV

    The World Health Organization (WHO) convened a Guideline Development Group (GDG) meeting from 29 to 31 July 2019 to review global guidance on contraceptive eligibility for women at high risk of HIV acquisition to and determine whether revisions to the fifth edition of the Medical eligibility criteria for...